Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
12/04/18
DUBLIN , Dec. 4, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.  (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018 , in New York City . Theravance Biopharma management and R&D teams will provide an
12/03/18
DUBLIN , Dec. 3, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMA SM   9% fixed rate term notes.
11/27/18
First-in-Human Study for Novel, Inhaled, Lung-Selective pan-Janus Kinase (JAK) Inhibitor with Potentially Broad Activity Across Range of Serious Respiratory Diseases DUBLIN , Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today
11/20/18
Study to Evaluate Novel, Potent, Orally Administered and Gut-Selective pan-Janus Kinase (JAK) Inhibitor in Patients with Moderately to Severely Active Crohn's Disease DUBLIN , Nov. 20, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today
11/19/18
DUBLIN , Nov. 19, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 2018 Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 at 3:50 p.m. ET .
11/12/18
DUBLIN , Nov. 12, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognizing the
11/09/18
YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US DUBLIN, Ireland , HERTFORDSHIRE, England and PITTSBURGH , Nov. 9, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan N.V.
11/07/18
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will present a corporate overview at the Credit Suisse 27 th Annual Healthcare Conference on Wednesday, November 14, 2018 , at 8:35 a.m. MST .  The conference will be held from November
11/06/18
PDUFA date for YUPELRI™ (revefenacin) inhalation solution on November 13 TD-1473 and TD-9855 entering late-stage clinical development programs; TD-8236 advancing from research into clinic Company to host R&D Day on December 12 in New York City DUBLIN , Nov.
11/06/18
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused